Hansen Niels, Bouter Caroline, Müller Sebastian Johannes, van Riesen Christoph, Khadhraoui Eya, Ernst Marielle, Riedel Christian Heiner, Wiltfang Jens, Lange Claudia
Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, 37075 Göttingen, Germany.
Department of Nuclear Medicine, University Medical Center Göttingen, 37075 Göttingen, Germany.
Brain Sci. 2023 Jan 31;13(2):242. doi: 10.3390/brainsci13020242.
Prodromal dementia with Lewy bodies (DLB) can emerge with the onset of mild cognitive impairment (MCI). Standard biomarkers can help identify such patients to improve therapy and treatment strategies. Our review aims to describe the latest evidence on promising biomarkers in prodromal DLB with MCI onset (MCI-LB).
We selected articles on different biomarkers in MCI-LB from PubMed and conducted a narrative review.
We identified potentially promising clinical biomarkers, e.g., (1) assessing autonomic symptoms specifically, (2) describing the cognitive profile in several subdomains including executive and visual functions, and (3) measuring the speed of speech. In addition, we describe the measurement of seeding amplification assays of alpha-synuclein in cerebrospinal fluid as a relevant biomarker for MCI-LB. Electroencephalographic markers, as in calculating the theta/beta ratio or intermittent delta activity, or analyzing peak frequency in electroencephalography-methods also potentially useful once they have been validated in large patient cohorts. The 18F fluorodesoxyglucose positron emission tomography (FDG-PET) technique is also discussed to investigate metabolic signatures, as well as a specific magnetic resonance imaging (MRI) technique such as for the volumetric region of interest analysis.
These biomarker results suggest that MCI-LB is a promising field for the use of biomarkers other than established ones to diagnose early prodromal DLB. Further large-scale studies are needed to better evaluate and subsequently use these promising biomarkers in prodromal DLB.
路易体前驱性痴呆（DLB）可在轻度认知障碍（MCI）发作时出现。标准生物标志物有助于识别此类患者，以改进治疗方法和策略。我们的综述旨在描述有关MCI起病的前驱性DLB（MCI-LB）中有前景的生物标志物的最新证据。
我们从PubMed上选择了关于MCI-LB中不同生物标志物的文章，并进行了叙述性综述。
我们确定了潜在有前景的临床生物标志物，例如，（1）专门评估自主神经症状，（2）描述包括执行功能和视觉功能在内的几个子领域的认知概况，以及（3）测量言语速度。此外，我们描述了脑脊液中α-突触核蛋白种子扩增测定的测量，作为MCI-LB的相关生物标志物。脑电图标记，如计算θ/β比值或间歇性δ活动，或分析脑电图方法中的峰值频率，一旦在大型患者队列中得到验证，这些方法也可能有用。还讨论了18F氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）技术以研究代谢特征，以及一种特定的磁共振成像（MRI）技术，如用于感兴趣区域的体积分析。
这些生物标志物结果表明，MCI-LB是一个有前景的领域，可使用既定生物标志物以外的生物标志物来诊断早期前驱性DLB。需要进一步的大规模研究，以更好地评估并随后在前驱性DLB中使用这些有前景的生物标志物。
